Cipla Ltd and Dr. Lal Pathlabs Share Q2 Results

5paisa Research Team 10th December 2022 - 04:31 pm

On 26th October, two important companies in the healthcare space viz. Cipla and Dr. Lal Pathlabs announced their quarterly results. Here is a gist of the numbers.

Cipla Ltd - Q2 Results

Cipla Ltd reported 9.56% higher sales for the Sep-21 quarter at Rs.5,520 crore. Net Profits for the Sep-21 quarter was up 6.90% at Rs.711 crore. Cipla has received a huge demand notice from the NPPA for overcharging under the DPCO. While the total demand is for Rs.3,703 crore, the matter is currently under litigation in the courts.

Rs in Crore	Sep-21	Sep-20	YOY	Jun-21	QOQ
Total Income (Rs cr)	₹ 5,519.80	₹ 5,038.29	9.56%	₹ 5,504.35	0.28%
Net Profit (Rs cr)	₹ 711.36	₹ 665.43	6.90%	₹ 714.72	-0.47%
Diluted EPS (Rs)	₹ 8.80	₹ 8.24		₹ 8.85
Net Margins	12.89%	13.21%		12.98%

During the quarter, Cipla did manage its raw material costs fairly well despite the supply chain constraints. However, spike in other expenses led to pressure on the profit growth. Net margins at 12.89% was lower than 13.21% on a yoy basis. Overall, the results had nothing remarkable about them in the quarter.

Dr. Lal Pathlabs - Q2 PAT Results

Dr. Lal Pathlabs reported 15.4% growth in sales in the Sep-21 quarter at Rs.498 crore. Net profits for the Sep-21 quarter was up by a more subdued 11.37% at Rs95cr. The board of Dr. Lal Pathlabs has approved the first dividend of 60% or Rs.6 per share on par value of Rs.10. In the first half of the financial year, the company generated 81% higher net cash from operations at Rs.282 crore.

Rs in Crore	Sep-21	Sep-20	YOY	Jun-21	QOQ
Total Income (Rs cr)	₹ 498.40	₹ 431.90	15.40%	₹ 606.60	-17.84%
Net Profit (Rs cr)	₹ 95.00	₹ 85.30	11.37%	₹ 131.20	-27.59%
Diluted EPS (Rs)	₹ 11.45	₹ 10.31		₹ 15.84
Net Margins	19.06%	19.75%		21.63%

With a sharp fall in COVID related testing and other medical revenues, the revenues and profits fell on a sequential basis. The profits over Sep-20 quarter grew in a more measured way because the raw material costs spiked by 25% during this period. Net margins at 19.06% was slightly lower than 19.75% in the Sep-20 quarter.

Also Read About:- Do You know About Indian Pharma Sector?

How do you rate this article?

Characters remaining (1500)

View All

5paisa Research Team

Get 100 trades FREE* with the code "FREEPACK"

+91

By Proceeding, you agree T&C*

Mobile No. belongs to

Discover more of what matters to you.

Business and ... Stock Recomme... Fintech Fundamental &... Market Outloo... Personal Fina... Futures and O... Indian Stock ... Commodities